BioNTech shares gained after a strong Q2 and oncology focus led BofA and Clear Street to raise price targets to $134 and $185, respectively. Revenue doubled YoY to 260.8 mn euro, with lower R&D costs and 16 bn euro in cash. Retail sentiment turned 'extremely bullish' as BioNTech reaffirmed 2025 guidance and eyed a $1.5 bn BMS deal.